Literature DB >> 556824

Serum creatine phosphokinase levels and prednisone treated muscle weakness.

T L Munsat, W G Bradley.   

Abstract

Evidence is cited from the literature and from personal experience with the "inflammatory" form of facioscapulohumeral syndrome that the creatine phosphokinase reduction occurring during pharmacologic treatment of various neuromuscular diseases does not necessarily imply therapeutic benefit.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 556824     DOI： 10.1212/wnl.27.1.96

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 2.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 3.  Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention.

Authors:  H Moser
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

Review 4.  Drug treatment for facioscapulohumeral muscular dystrophy.

Authors:  M R Rose; R Tawil
Journal:  Cochrane Database Syst Rev       Date:  2004

5.  Sporadic distal myopathy.

Authors:  M L Vaccario; C Scoppetta; R Bracaglia; A Uncini
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Familial oculopharyngeal muscular dystrophy with distal spread.

Authors:  G Vita; R Dattola; M Santoro; C Messina
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

7.  In vivo effects of protease inhibitors on chickens with hereditary muscular dystrophy.

Authors:  M S Hudecki; C M Pollina; R R Heffner
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.